Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Core Insights - AnaptysBio reported positive Phase 2b data for rosnilimab in rheumatoid arthritis, demonstrating impressive safety, tolerability, and sustained efficacy [2][4] - The company has a strong cash position of approximately $420 million, ensuring funding through the end of 2027 [2][8] - Upcoming data releases include full clinical results for rosnilimab in rheumatoid arthritis in Q2 2025 and top-line Phase 2 data for ulcerative colitis in Q4 2025 [2][4] Financial Performance - For Q4 2024, collaboration revenue was $43.1 million, a significant increase from $9.0 million in Q4 2023 [10][11] - The net loss for Q4 2024 was $21.8 million, compared to a net loss of $42.2 million in Q4 2023, indicating improved financial performance [14][17] - Research and development expenses increased to $42.6 million for Q4 2024 from $33.5 million in Q4 2023, primarily due to costs associated with rosnilimab and other candidates [14][17] Clinical Development Updates - Rosnilimab achieved statistical significance on primary and key secondary endpoints in the Phase 2b trial for rheumatoid arthritis, with 69% of treated patients achieving low disease activity [5][10] - Phase 1 trials for ANB033 and ANB101 are progressing as planned, with ANB101 set to initiate this quarter [2][4] - An exclusive global license agreement with Vanda Pharmaceuticals was announced for imsidolimab, an IL-36R antagonist, which includes potential future milestone payments and royalties [4][10] Asset Portfolio - The company is advancing its lead program, rosnilimab, in both rheumatoid arthritis and ulcerative colitis, with significant data expected in 2025 [2][4] - Other candidates in development include ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator, both in early-stage trials [6][12] - The collaboration with GSK has shown strong commercial performance, particularly with Jemperli, which reported $190 million in Q4 2024 sales [10][11]